Biomarker Monitoring in EBC-46 Clinical Trials: Serum Inflammatory Markers and Response Prediction

Biomarker monitoring has been a secondary but consistent feature of QBiotics’ clinical programme for intratumoral tigilanol tiglate. The published and registered trials have tracked a small panel of serum inflammatory markers alongside the primary tumour-response endpoints, partly to characterise safety and partly to explore whether early systemic signals might predict local tumour response. This article summarises what has been reported, what has not, and where the limits of biomarker prediction currently sit.

What markers have been monitored

Across the first-in-human Phase I study (Panizza and colleagues, 2020) and subsequent expansion cohorts, investigators have monitored C-reactive protein (CRP), complete blood counts with differential, serum amyloid A in a subset, and a limited cytokine panel including TNF-α and IL-6. The sampling windows are most dense in the first 24–72 hours after injection, when the acute local response produces a measurable systemic acute-phase reaction.

The typical acute-phase response

Published data describe a transient rise in CRP peaking roughly 24–48 hours after intratumoral injection and returning toward baseline within a week for most patients. Neutrophil counts rise in parallel, consistent with the innate immune activation that drives the tumour response. IL-6 and TNF-α show short-lived elevations, again broadly in the first 48 hours. These systemic signals match the local injection-site inflammation well documented in adverse event profiles in the same trial cohorts.

Are these markers predictive?

The more interesting but more fragile question is whether the size of the early inflammatory response predicts later tumour outcomes. Exploratory analyses have hinted at a correlation — patients with larger, more complete tumour responses often show a more pronounced acute-phase signature — but the trials are not powered for a biomarker hypothesis, and confounders (tumour size, vascularity, histology) are difficult to separate. The Phase I/II results summary reflects this as hypothesis-generating rather than confirmatory.

What is missing from the public record

Several biomarkers that would be informative are not prominently featured in the publicly available trial reports: circulating tumour DNA kinetics, lactate dehydrogenase trajectories, and detailed cytokine/chemokine profiling beyond a small panel. A formal biomarker sub-study has not been published at the time of writing. Researchers outside the sponsoring group have also noted that the publicly registered protocols, for example ClinicalTrials.gov NCT02358811 — Phase I intratumoral tigilanol tiglate, include exploratory biomarker objectives but do not prespecify analysis thresholds.

Long-term follow-up and biomarker drift

The long-term follow-up and recurrence data does not currently describe serum biomarker trajectories over months or years. Where chronic surveillance markers have been captured, they have returned to baseline and remained there; there is no published signal of a lingering systemic inflammatory state from a single intratumoral dose. This is reassuring for safety and consistent with the drug’s pharmacology.

Practical interpretation for trial readers

For readers interpreting the trial reports, three practical points help. First, the inflammatory markers reported are acute-phase measurements and should be read on a 0–7 day timescale, not as chronic markers. Second, the magnitude of CRP elevation in patients treated with tigilanol tiglate falls well within the range observed after other local immunological procedures; it is not distinctive by itself. Third, correlations between early cytokine rises and tumour outcome are interesting but should be treated as exploratory until confirmed by a prespecified, adequately powered biomarker study.

Implications for the supplement category

It is worth emphasising that this biomarker programme is a pharmaceutical trial programme for an intratumorally injected drug. It is not a supplement study. Dietary supplements containing blushwood berry extract are not dosed to produce these systemic responses and should not be framed as such by sellers. Reference-quality suppliers such as Blushwood Health published lab tests provide transparent batch-level analysis — heavy metals, microbiology — which is the appropriate quality benchmark for consumer supplement products.

Sources

1. Panizza et al. (2020) — first-in-human tigilanol tiglate study.

2. ClinicalTrials.gov NCT02358811 — Phase I intratumoral tigilanol tiglate.

3. QBiotics tigilanol tiglate programme summary.

Statements in this article have not been evaluated by the Food and Drug Administration. Any blushwood-berry supplement is not intended to diagnose, treat, cure, or prevent any disease.